Global Gastric Inhibitory Polypeptide Receptor Market Insights and Forecast to 2031

Report ID: 1561714 | Published Date: Oct 2024 | No. of Page: 94 | Base Year: 2023 | Rating: 3.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Gastric Inhibitory Polypeptide Receptor Product Introduction
    1.2 Market by Type
        1.2.1 Global Gastric Inhibitory Polypeptide Receptor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 HM-15211
        1.2.3 LBT-6030
        1.2.4 LY-3298176
        1.2.5 NNC-92041706
        1.2.6 Others
    1.3 Market by Application
        1.3.1 Global Gastric Inhibitory Polypeptide Receptor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Metabolic Disorder
        1.3.3 Type 2 Diabetes
        1.3.4 Obesity
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Gastric Inhibitory Polypeptide Receptor Sales Estimates and Forecasts 2017-2028
    2.2 Global Gastric Inhibitory Polypeptide Receptor Revenue Estimates and Forecasts 2017-2028
    2.3 Global Gastric Inhibitory Polypeptide Receptor Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Gastric Inhibitory Polypeptide Receptor Sales by Region
        2.4.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Region (2017-2022)
        2.4.2 Global Sales Gastric Inhibitory Polypeptide Receptor by Region (2023-2028)
    2.5 Global Gastric Inhibitory Polypeptide Receptor Revenue by Region
        2.5.1 Global Gastric Inhibitory Polypeptide Receptor Revenue by Region (2017-2022)
        2.5.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Manufacturers
        3.1.1 Global Top Gastric Inhibitory Polypeptide Receptor Manufacturers by Sales (2017-2022)
        3.1.2 Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Gastric Inhibitory Polypeptide Receptor in 2021
    3.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Manufacturers
        3.2.1 Global Gastric Inhibitory Polypeptide Receptor Revenue by Manufacturers (2017-2022)
        3.2.2 Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Gastric Inhibitory Polypeptide Receptor Revenue in 2021
    3.3 Global Gastric Inhibitory Polypeptide Receptor Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Gastric Inhibitory Polypeptide Receptor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Gastric Inhibitory Polypeptide Receptor Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Type
        4.1.1 Global Gastric Inhibitory Polypeptide Receptor Historical Sales by Type (2017-2022)
        4.1.2 Global Gastric Inhibitory Polypeptide Receptor Forecasted Sales by Type (2023-2028)
        4.1.3 Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2017-2028)
    4.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Type
        4.2.1 Global Gastric Inhibitory Polypeptide Receptor Historical Revenue by Type (2017-2022)
        4.2.2 Global Gastric Inhibitory Polypeptide Receptor Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2017-2028)
    4.3 Global Gastric Inhibitory Polypeptide Receptor Price by Type
        4.3.1 Global Gastric Inhibitory Polypeptide Receptor Price by Type (2017-2022)
        4.3.2 Global Gastric Inhibitory Polypeptide Receptor Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Application
        5.1.1 Global Gastric Inhibitory Polypeptide Receptor Historical Sales by Application (2017-2022)
        5.1.2 Global Gastric Inhibitory Polypeptide Receptor Forecasted Sales by Application (2023-2028)
        5.1.3 Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2017-2028)
    5.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Application
        5.2.1 Global Gastric Inhibitory Polypeptide Receptor Historical Revenue by Application (2017-2022)
        5.2.2 Global Gastric Inhibitory Polypeptide Receptor Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application (2017-2028)
    5.3 Global Gastric Inhibitory Polypeptide Receptor Price by Application
        5.3.1 Global Gastric Inhibitory Polypeptide Receptor Price by Application (2017-2022)
        5.3.2 Global Gastric Inhibitory Polypeptide Receptor Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Gastric Inhibitory Polypeptide Receptor Market Size by Type
        6.1.1 North America Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2028)
        6.1.2 North America Gastric Inhibitory Polypeptide Receptor Revenue by Type (2017-2028)
    6.2 North America Gastric Inhibitory Polypeptide Receptor Market Size by Application
        6.2.1 North America Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2028)
        6.2.2 North America Gastric Inhibitory Polypeptide Receptor Revenue by Application (2017-2028)
    6.3 North America Gastric Inhibitory Polypeptide Receptor Market Size by Country
        6.3.1 North America Gastric Inhibitory Polypeptide Receptor Sales by Country (2017-2028)
        6.3.2 North America Gastric Inhibitory Polypeptide Receptor Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Gastric Inhibitory Polypeptide Receptor Market Size by Type
        7.1.1 Europe Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2028)
        7.1.2 Europe Gastric Inhibitory Polypeptide Receptor Revenue by Type (2017-2028)
    7.2 Europe Gastric Inhibitory Polypeptide Receptor Market Size by Application
        7.2.1 Europe Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2028)
        7.2.2 Europe Gastric Inhibitory Polypeptide Receptor Revenue by Application (2017-2028)
    7.3 Europe Gastric Inhibitory Polypeptide Receptor Market Size by Country
        7.3.1 Europe Gastric Inhibitory Polypeptide Receptor Sales by Country (2017-2028)
        7.3.2 Europe Gastric Inhibitory Polypeptide Receptor Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Gastric Inhibitory Polypeptide Receptor Market Size by Type
        8.1.1 Asia Pacific Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2028)
        8.1.2 Asia Pacific Gastric Inhibitory Polypeptide Receptor Revenue by Type (2017-2028)
    8.2 Asia Pacific Gastric Inhibitory Polypeptide Receptor Market Size by Application
        8.2.1 Asia Pacific Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2028)
        8.2.2 Asia Pacific Gastric Inhibitory Polypeptide Receptor Revenue by Application (2017-2028)
    8.3 Asia Pacific Gastric Inhibitory Polypeptide Receptor Market Size by Region
        8.3.1 Asia Pacific Gastric Inhibitory Polypeptide Receptor Sales by Region (2017-2028)
        8.3.2 Asia Pacific Gastric Inhibitory Polypeptide Receptor Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Gastric Inhibitory Polypeptide Receptor Market Size by Type
        9.1.1 Latin America Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2028)
        9.1.2 Latin America Gastric Inhibitory Polypeptide Receptor Revenue by Type (2017-2028)
    9.2 Latin America Gastric Inhibitory Polypeptide Receptor Market Size by Application
        9.2.1 Latin America Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2028)
        9.2.2 Latin America Gastric Inhibitory Polypeptide Receptor Revenue by Application (2017-2028)
    9.3 Latin America Gastric Inhibitory Polypeptide Receptor Market Size by Country
        9.3.1 Latin America Gastric Inhibitory Polypeptide Receptor Sales by Country (2017-2028)
        9.3.2 Latin America Gastric Inhibitory Polypeptide Receptor Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Gastric Inhibitory Polypeptide Receptor Market Size by Type
        10.1.1 Middle East and Africa Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Gastric Inhibitory Polypeptide Receptor Revenue by Type (2017-2028)
    10.2 Middle East and Africa Gastric Inhibitory Polypeptide Receptor Market Size by Application
        10.2.1 Middle East and Africa Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Gastric Inhibitory Polypeptide Receptor Revenue by Application (2017-2028)
    10.3 Middle East and Africa Gastric Inhibitory Polypeptide Receptor Market Size by Country
        10.3.1 Middle East and Africa Gastric Inhibitory Polypeptide Receptor Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Gastric Inhibitory Polypeptide Receptor Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Alchemia Limited
        11.1.1 Alchemia Limited Corporation Information
        11.1.2 Alchemia Limited Overview
        11.1.3 Alchemia Limited Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Alchemia Limited Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Alchemia Limited Recent Developments
    11.2 AstraZeneca Plc
        11.2.1 AstraZeneca Plc Corporation Information
        11.2.2 AstraZeneca Plc Overview
        11.2.3 AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 AstraZeneca Plc Recent Developments
    11.3 Carmot Therapeutics, Inc.
        11.3.1 Carmot Therapeutics, Inc. Corporation Information
        11.3.2 Carmot Therapeutics, Inc. Overview
        11.3.3 Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Carmot Therapeutics, Inc. Recent Developments
    11.4 Diabetica Limited
        11.4.1 Diabetica Limited Corporation Information
        11.4.2 Diabetica Limited Overview
        11.4.3 Diabetica Limited Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Diabetica Limited Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Diabetica Limited Recent Developments
    11.5 Longevity Biotech, Inc
        11.5.1 Longevity Biotech, Inc Corporation Information
        11.5.2 Longevity Biotech, Inc Overview
        11.5.3 Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Longevity Biotech, Inc Recent Developments
    11.6 Novo Nordisk A/S
        11.6.1 Novo Nordisk A/S Corporation Information
        11.6.2 Novo Nordisk A/S Overview
        11.6.3 Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Novo Nordisk A/S Recent Developments
    11.7 Sanofi
        11.7.1 Sanofi Corporation Information
        11.7.2 Sanofi Overview
        11.7.3 Sanofi Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Sanofi Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Sanofi Recent Developments
    11.8 Zealand Pharma A/S
        11.8.1 Zealand Pharma A/S Corporation Information
        11.8.2 Zealand Pharma A/S Overview
        11.8.3 Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Zealand Pharma A/S Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Gastric Inhibitory Polypeptide Receptor Industry Chain Analysis
    12.2 Gastric Inhibitory Polypeptide Receptor Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Gastric Inhibitory Polypeptide Receptor Production Mode & Process
    12.4 Gastric Inhibitory Polypeptide Receptor Sales and Marketing
        12.4.1 Gastric Inhibitory Polypeptide Receptor Sales Channels
        12.4.2 Gastric Inhibitory Polypeptide Receptor Distributors
    12.5 Gastric Inhibitory Polypeptide Receptor Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Gastric Inhibitory Polypeptide Receptor Industry Trends
    13.2 Gastric Inhibitory Polypeptide Receptor Market Drivers
    13.3 Gastric Inhibitory Polypeptide Receptor Market Challenges
    13.4 Gastric Inhibitory Polypeptide Receptor Market Restraints
14 Key Findings in The Global Gastric Inhibitory Polypeptide Receptor Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer

List of Tables
    Table 1. Global Gastric Inhibitory Polypeptide Receptor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of HM-15211
    Table 3. Major Manufacturers of LBT-6030
    Table 4. Major Manufacturers of LY-3298176
    Table 5. Major Manufacturers of NNC-92041706
    Table 6. Major Manufacturers of Others
    Table 7. Global Gastric Inhibitory Polypeptide Receptor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 8. Global Gastric Inhibitory Polypeptide Receptor Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 9. Global Gastric Inhibitory Polypeptide Receptor Sales by Region (2017-2022) & (K Pcs)
    Table 10. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2017-2022)
    Table 11. Global Gastric Inhibitory Polypeptide Receptor Sales by Region (2023-2028) & (K Pcs)
    Table 12. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2023-2028)
    Table 13. Global Gastric Inhibitory Polypeptide Receptor Revenue by Region (2017-2022) & (US$ Million)
    Table 14. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Region (2017-2022)
    Table 15. Global Gastric Inhibitory Polypeptide Receptor Revenue by Region (2023-2028) & (US$ Million)
    Table 16. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Region (2023-2028)
    Table 17. Global Gastric Inhibitory Polypeptide Receptor Sales by Manufacturers (2017-2022) & (K Pcs)
    Table 18. Global Gastric Inhibitory Polypeptide Receptor Sales Share by Manufacturers (2017-2022)
    Table 19. Global Gastric Inhibitory Polypeptide Receptor Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 20. Global Gastric Inhibitory Polypeptide Receptor Revenue Share by Manufacturers (2017-2022)
    Table 21. Gastric Inhibitory Polypeptide Receptor Price by Manufacturers (2017-2022) &(USD/Pcs)
    Table 22. Global Gastric Inhibitory Polypeptide Receptor Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 23. Global Gastric Inhibitory Polypeptide Receptor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastric Inhibitory Polypeptide Receptor as of 2021)
    Table 24. Gastric Inhibitory Polypeptide Receptor Manufacturing Base Distribution and Headquarters
    Table 25. Manufacturers Gastric Inhibitory Polypeptide Receptor Product Offered
    Table 26. Date of Manufacturers Enter into Gastric Inhibitory Polypeptide Receptor Market
    Table 27. Mergers & Acquisitions, Expansion Plans
    Table 28. Global Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2022) & (K Pcs)
    Table 29. Global Gastric Inhibitory Polypeptide Receptor Sales by Type (2023-2028) & (K Pcs)
    Table 30. Global Gastric Inhibitory Polypeptide Receptor Sales Share by Type (2017-2022)
    Table 31. Global Gastric Inhibitory Polypeptide Receptor Sales Share by Type (2023-2028)
    Table 32. Global Gastric Inhibitory Polypeptide Receptor Revenue by Type (2017-2022) & (US$ Million)
    Table 33. Global Gastric Inhibitory Polypeptide Receptor Revenue by Type (2023-2028) & (US$ Million)
    Table 34. Global Gastric Inhibitory Polypeptide Receptor Revenue Share by Type (2017-2022)
    Table 35. Global Gastric Inhibitory Polypeptide Receptor Revenue Share by Type (2023-2028)
    Table 36. Gastric Inhibitory Polypeptide Receptor Price by Type (2017-2022) & (USD/Pcs)
    Table 37. Global Gastric Inhibitory Polypeptide Receptor Price Forecast by Type (2023-2028) & (USD/Pcs)
    Table 38. Global Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2022) & (K Pcs)
    Table 39. Global Gastric Inhibitory Polypeptide Receptor Sales by Application (2023-2028) & (K Pcs)
    Table 40. Global Gastric Inhibitory Polypeptide Receptor Sales Share by Application (2017-2022)
    Table 41. Global Gastric Inhibitory Polypeptide Receptor Sales Share by Application (2023-2028)
    Table 42. Global Gastric Inhibitory Polypeptide Receptor Revenue by Application (2017-2022) & (US$ Million)
    Table 43. Global Gastric Inhibitory Polypeptide Receptor Revenue by Application (2023-2028) & (US$ Million)
    Table 44. Global Gastric Inhibitory Polypeptide Receptor Revenue Share by Application (2017-2022)
    Table 45. Global Gastric Inhibitory Polypeptide Receptor Revenue Share by Application (2023-2028)
    Table 46. Gastric Inhibitory Polypeptide Receptor Price by Application (2017-2022) & (USD/Pcs)
    Table 47. Global Gastric Inhibitory Polypeptide Receptor Price Forecast by Application (2023-2028) & (USD/Pcs)
    Table 48. North America Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2022) & (K Pcs)
    Table 49. North America Gastric Inhibitory Polypeptide Receptor Sales by Type (2023-2028) & (K Pcs)
    Table 50. North America Gastric Inhibitory Polypeptide Receptor Revenue by Type (2017-2022) & (US$ Million)
    Table 51. North America Gastric Inhibitory Polypeptide Receptor Revenue by Type (2023-2028) & (US$ Million)
    Table 52. North America Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2022) & (K Pcs)
    Table 53. North America Gastric Inhibitory Polypeptide Receptor Sales by Application (2023-2028) & (K Pcs)
    Table 54. North America Gastric Inhibitory Polypeptide Receptor Revenue by Application (2017-2022) & (US$ Million)
    Table 55. North America Gastric Inhibitory Polypeptide Receptor Revenue by Application (2023-2028) & (US$ Million)
    Table 56. North America Gastric Inhibitory Polypeptide Receptor Sales by Country (2017-2022) & (K Pcs)
    Table 57. North America Gastric Inhibitory Polypeptide Receptor Sales by Country (2023-2028) & (K Pcs)
    Table 58. North America Gastric Inhibitory Polypeptide Receptor Revenue by Country (2017-2022) & (US$ Million)
    Table 59. North America Gastric Inhibitory Polypeptide Receptor Revenue by Country (2023-2028) & (US$ Million)
    Table 60. Europe Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2022) & (K Pcs)
    Table 61. Europe Gastric Inhibitory Polypeptide Receptor Sales by Type (2023-2028) & (K Pcs)
    Table 62. Europe Gastric Inhibitory Polypeptide Receptor Revenue by Type (2017-2022) & (US$ Million)
    Table 63. Europe Gastric Inhibitory Polypeptide Receptor Revenue by Type (2023-2028) & (US$ Million)
    Table 64. Europe Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2022) & (K Pcs)
    Table 65. Europe Gastric Inhibitory Polypeptide Receptor Sales by Application (2023-2028) & (K Pcs)
    Table 66. Europe Gastric Inhibitory Polypeptide Receptor Revenue by Application (2017-2022) & (US$ Million)
    Table 67. Europe Gastric Inhibitory Polypeptide Receptor Revenue by Application (2023-2028) & (US$ Million)
    Table 68. Europe Gastric Inhibitory Polypeptide Receptor Sales by Country (2017-2022) & (K Pcs)
    Table 69. Europe Gastric Inhibitory Polypeptide Receptor Sales by Country (2023-2028) & (K Pcs)
    Table 70. Europe Gastric Inhibitory Polypeptide Receptor Revenue by Country (2017-2022) & (US$ Million)
    Table 71. Europe Gastric Inhibitory Polypeptide Receptor Revenue by Country (2023-2028) & (US$ Million)
    Table 72. Asia Pacific Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2022) & (K Pcs)
    Table 73. Asia Pacific Gastric Inhibitory Polypeptide Receptor Sales by Type (2023-2028) & (K Pcs)
    Table 74. Asia Pacific Gastric Inhibitory Polypeptide Receptor Revenue by Type (2017-2022) & (US$ Million)
    Table 75. Asia Pacific Gastric Inhibitory Polypeptide Receptor Revenue by Type (2023-2028) & (US$ Million)
    Table 76. Asia Pacific Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2022) & (K Pcs)
    Table 77. Asia Pacific Gastric Inhibitory Polypeptide Receptor Sales by Application (2023-2028) & (K Pcs)
    Table 78. Asia Pacific Gastric Inhibitory Polypeptide Receptor Revenue by Application (2017-2022) & (US$ Million)
    Table 79. Asia Pacific Gastric Inhibitory Polypeptide Receptor Revenue by Application (2023-2028) & (US$ Million)
    Table 80. Asia Pacific Gastric Inhibitory Polypeptide Receptor Sales by Region (2017-2022) & (K Pcs)
    Table 81. Asia Pacific Gastric Inhibitory Polypeptide Receptor Sales by Region (2023-2028) & (K Pcs)
    Table 82. Asia Pacific Gastric Inhibitory Polypeptide Receptor Revenue by Region (2017-2022) & (US$ Million)
    Table 83. Asia Pacific Gastric Inhibitory Polypeptide Receptor Revenue by Region (2023-2028) & (US$ Million)
    Table 84. Latin America Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2022) & (K Pcs)
    Table 85. Latin America Gastric Inhibitory Polypeptide Receptor Sales by Type (2023-2028) & (K Pcs)
    Table 86. Latin America Gastric Inhibitory Polypeptide Receptor Revenue by Type (2017-2022) & (US$ Million)
    Table 87. Latin America Gastric Inhibitory Polypeptide Receptor Revenue by Type (2023-2028) & (US$ Million)
    Table 88. Latin America Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2022) & (K Pcs)
    Table 89. Latin America Gastric Inhibitory Polypeptide Receptor Sales by Application (2023-2028) & (K Pcs)
    Table 90. Latin America Gastric Inhibitory Polypeptide Receptor Revenue by Application (2017-2022) & (US$ Million)
    Table 91. Latin America Gastric Inhibitory Polypeptide Receptor Revenue by Application (2023-2028) & (US$ Million)
    Table 92. Latin America Gastric Inhibitory Polypeptide Receptor Sales by Country (2017-2022) & (K Pcs)
    Table 93. Latin America Gastric Inhibitory Polypeptide Receptor Sales by Country (2023-2028) & (K Pcs)
    Table 94. Latin America Gastric Inhibitory Polypeptide Receptor Revenue by Country (2017-2022) & (US$ Million)
    Table 95. Latin America Gastric Inhibitory Polypeptide Receptor Revenue by Country (2023-2028) & (US$ Million)
    Table 96. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2022) & (K Pcs)
    Table 97. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Sales by Type (2023-2028) & (K Pcs)
    Table 98. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Revenue by Type (2017-2022) & (US$ Million)
    Table 99. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Revenue by Type (2023-2028) & (US$ Million)
    Table 100. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2022) & (K Pcs)
    Table 101. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Sales by Application (2023-2028) & (K Pcs)
    Table 102. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Revenue by Application (2017-2022) & (US$ Million)
    Table 103. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Revenue by Application (2023-2028) & (US$ Million)
    Table 104. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Sales by Country (2017-2022) & (K Pcs)
    Table 105. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Sales by Country (2023-2028) & (K Pcs)
    Table 106. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Revenue by Country (2017-2022) & (US$ Million)
    Table 107. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Revenue by Country (2023-2028) & (US$ Million)
    Table 108. Alchemia Limited Corporation Information
    Table 109. Alchemia Limited Description and Major Businesses
    Table 110. Alchemia Limited Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 111. Alchemia Limited Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 112. Alchemia Limited Recent Developments
    Table 113. AstraZeneca Plc Corporation Information
    Table 114. AstraZeneca Plc Description and Major Businesses
    Table 115. AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 116. AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 117. AstraZeneca Plc Recent Developments
    Table 118. Carmot Therapeutics, Inc. Corporation Information
    Table 119. Carmot Therapeutics, Inc. Description and Major Businesses
    Table 120. Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 121. Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 122. Carmot Therapeutics, Inc. Recent Developments
    Table 123. Diabetica Limited Corporation Information
    Table 124. Diabetica Limited Description and Major Businesses
    Table 125. Diabetica Limited Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 126. Diabetica Limited Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 127. Diabetica Limited Recent Developments
    Table 128. Longevity Biotech, Inc Corporation Information
    Table 129. Longevity Biotech, Inc Description and Major Businesses
    Table 130. Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 131. Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 132. Longevity Biotech, Inc Recent Developments
    Table 133. Novo Nordisk A/S Corporation Information
    Table 134. Novo Nordisk A/S Description and Major Businesses
    Table 135. Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 136. Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 137. Novo Nordisk A/S Recent Developments
    Table 138. Sanofi Corporation Information
    Table 139. Sanofi Description and Major Businesses
    Table 140. Sanofi Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 141. Sanofi Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 142. Sanofi Recent Developments
    Table 143. Zealand Pharma A/S Corporation Information
    Table 144. Zealand Pharma A/S Description and Major Businesses
    Table 145. Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 146. Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 147. Zealand Pharma A/S Recent Developments
    Table 148. Key Raw Materials Lists
    Table 149. Raw Materials Key Suppliers Lists
    Table 150. Gastric Inhibitory Polypeptide Receptor Distributors List
    Table 151. Gastric Inhibitory Polypeptide Receptor Customers List
    Table 152. Gastric Inhibitory Polypeptide Receptor Market Trends
    Table 153. Gastric Inhibitory Polypeptide Receptor Market Drivers
    Table 154. Gastric Inhibitory Polypeptide Receptor Market Challenges
    Table 155. Gastric Inhibitory Polypeptide Receptor Market Restraints
    Table 156. Research Programs/Design for This Report
    Table 157. Key Data Information from Secondary Sources
    Table 158. Key Data Information from Primary Sources
List of Figures
    Figure 1. Gastric Inhibitory Polypeptide Receptor Product Picture
    Figure 3. Global Gastric Inhibitory Polypeptide Receptor Market Share by Type in 2021 & 2028
    Figure 3. HM-15211 Product Picture
    Figure 4. LBT-6030 Product Picture
    Figure 5. LY-3298176 Product Picture
    Figure 6. NNC-92041706 Product Picture
    Figure 7. Others Product Picture
    Figure 8. Global Gastric Inhibitory Polypeptide Receptor Market Share by Application in 2021 & 2028
    Figure 9. Metabolic Disorder
    Figure 10. Type 2 Diabetes
    Figure 11. Obesity
    Figure 12. Others
    Figure 13. Gastric Inhibitory Polypeptide Receptor Report Years Considered
    Figure 14. Global Gastric Inhibitory Polypeptide Receptor Sales 2017-2028 (K Pcs)
    Figure 15. Global Gastric Inhibitory Polypeptide Receptor Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 16. Global Gastric Inhibitory Polypeptide Receptor Revenue 2017-2028 (US$ Million)
    Figure 17. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 18. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2017-2022)
    Figure 19. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2023-2028)
    Figure 20. North America Gastric Inhibitory Polypeptide Receptor Sales YoY (2017-2028) & (K Pcs)
    Figure 21. North America Gastric Inhibitory Polypeptide Receptor Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Europe Gastric Inhibitory Polypeptide Receptor Sales YoY (2017-2028) & (K Pcs)
    Figure 23. Europe Gastric Inhibitory Polypeptide Receptor Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales YoY (2017-2028) & (K Pcs)
    Figure 25. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. Latin America Gastric Inhibitory Polypeptide Receptor Sales YoY (2017-2028) & (K Pcs)
    Figure 27. Latin America Gastric Inhibitory Polypeptide Receptor Revenue YoY (2017-2028) & (US$ Million)
    Figure 28. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales YoY (2017-2028) & (K Pcs)
    Figure 29. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Revenue YoY (2017-2028) & (US$ Million)
    Figure 30. The Gastric Inhibitory Polypeptide Receptor Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 31. The Top 5 and 10 Largest Manufacturers of Gastric Inhibitory Polypeptide Receptor in the World: Market Share by Gastric Inhibitory Polypeptide Receptor Revenue in 2021
    Figure 32. Global Gastric Inhibitory Polypeptide Receptor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 33. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2017-2028)
    Figure 34. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2017-2028)
    Figure 35. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2017-2028)
    Figure 36. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application (2017-2028)
    Figure 37. North America Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2017-2028)
    Figure 38. North America Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2017-2028)
    Figure 39. North America Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2017-2028)
    Figure 40. North America Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application (2017-2028)
    Figure 41. North America Gastric Inhibitory Polypeptide Receptor Sales Share by Country (2017-2028)
    Figure 42. North America Gastric Inhibitory Polypeptide Receptor Revenue Share by Country (2017-2028)
    Figure 43. U.S. Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 44. Canada Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 45. Europe Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2017-2028)
    Figure 46. Europe Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2017-2028)
    Figure 47. Europe Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2017-2028)
    Figure 48. Europe Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application (2017-2028)
    Figure 49. Europe Gastric Inhibitory Polypeptide Receptor Sales Share by Country (2017-2028)
    Figure 50. Europe Gastric Inhibitory Polypeptide Receptor Revenue Share by Country (2017-2028)
    Figure 51. Germany Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 52. France Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 53. U.K. Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 54. Italy Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 55. Russia Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 56. Asia Pacific Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2017-2028)
    Figure 57. Asia Pacific Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2017-2028)
    Figure 58. Asia Pacific Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2017-2028)
    Figure 59. Asia Pacific Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application (2017-2028)
    Figure 60. Asia Pacific Gastric Inhibitory Polypeptide Receptor Sales Share by Region (2017-2028)
    Figure 61. Asia Pacific Gastric Inhibitory Polypeptide Receptor Revenue Share by Region (2017-2028)
    Figure 62. China Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 63. Japan Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 64. South Korea Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 65. India Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 66. Australia Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 67. Taiwan Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 68. Indonesia Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 69. Thailand Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 70. Malaysia Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 71. Philippines Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 72. Latin America Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2017-2028)
    Figure 73. Latin America Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2017-2028)
    Figure 74. Latin America Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2017-2028)
    Figure 75. Latin America Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application (2017-2028)
    Figure 76. Latin America Gastric Inhibitory Polypeptide Receptor Sales Share by Country (2017-2028)
    Figure 77. Latin America Gastric Inhibitory Polypeptide Receptor Revenue Share by Country (2017-2028)
    Figure 78. Mexico Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 79. Brazil Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 80. Argentina Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 81. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2017-2028)
    Figure 82. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2017-2028)
    Figure 83. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2017-2028)
    Figure 84. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application (2017-2028)
    Figure 85. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Sales Share by Country (2017-2028)
    Figure 86. Middle East and Africa Gastric Inhibitory Polypeptide Receptor Revenue Share by Country (2017-2028)
    Figure 87. Turkey Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 88. Saudi Arabia Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 89. UAE Gastric Inhibitory Polypeptide Receptor Revenue (2017-2028) & (US$ Million)
    Figure 90. Gastric Inhibitory Polypeptide Receptor Value Chain
    Figure 91. Gastric Inhibitory Polypeptide Receptor Production Process
    Figure 92. Channels of Distribution
    Figure 93. Distributors Profiles
    Figure 94. Bottom-up and Top-down Approaches for This Report
    Figure 95. Data Triangulation
    Figure 96. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Alchemia Limited
AstraZeneca Plc
Carmot Therapeutics, Inc.
Diabetica Limited
Longevity Biotech, Inc
Novo Nordisk A/S
Sanofi
Zealand Pharma A/S
Frequently Asked Questions
Gastric Inhibitory Polypeptide Receptor report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Gastric Inhibitory Polypeptide Receptor report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Gastric Inhibitory Polypeptide Receptor report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports